Effects of Release-Active Antibodies to CD4 Receptor on the Level of lck-Kinase in Cultured Mononuclear Cells from Human Peripheral Blood

Bulletin of Experimental Biology and Medicine

Volumn 162, Issue 3, 2017, Pages 323-326

  Emel'yanova A G ^a   Grechenko, V V ^b   Petrova, N V ^a   Shilovskii, I P ^c   Gorbunov, E A ^b   Tarasov, S A ^b   Khaitov, M R ^c   Morozov, S G ^a   Epshtein, O I ^a  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b Materia Medica Holding Research and Production Company   (Russian Federation)

^c FEDERAL BIOMEDICAL AGENCY OF RUSSIA   (Russian Federation)

Author keywords

antibodies; CD4; Ergoferon; lck kinase; release activity

Indexed keywords

CD4 ANTIBODY; CD4 ANTIGEN; PHYTOHEMAGGLUTININ; PROTEIN KINASE LCK; T LYMPHOCYTE RECEPTOR; ANTIBODY;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN CONTENT; PROTEIN EXPRESSION; CD4+ T LYMPHOCYTE; CYTOLOGY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; PRIMARY CELL CULTURE;

ADULT; ANTIBODIES; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MALE; PHYTOHEMAGGLUTININS; PRIMARY CELL CULTURE;

EID: 85009480719     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-017-3606-4     Document Type: Article

References (15)

1. Averyanov AV, Babkin AP, Bart BYa, Volchetsky AL, Minina ES, Kozyrev OA, Kostinov MP, Petrov DV, Selkova EP, Putilovsky MA, Nechaev VB, Epstein OI, Andrianova EN. Ergoferon and Oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial. Antibiotiki Khimioterapiya. 2012;57(7-8):23-30. Russian.
2. Tarasov SA, Kachanova MV, Gorbunov EA, Zabolotneva JA, Kheifets IA, Belopolskaya MV, Borodavkina MV, Dugina JL, Sergeeva SA, Epstein OI. Anaferon — effective medicine for treatment and prophylaxis a wide spectrum of infections. Vestn. Mezhdunar. Akad. Nauk. Russ. Sektsiya. 2010(1):23-27. Russian.
3. Shamsheva OV, Sokolov SA, Polesko IV. Thirty years of experience of ribosomal vaccine application in pediatrics. Detskie Infektsii. 2014;13(1):39-43. Russian.
4. Shilovsky IP, Kornilaeva GV, Khaitov MR. Novel possibilities for the treatment of the respiratory-syncytial viral infection: the results of the preclinical study of Ergoferon. Immunologiya. 2012;33(3):144-148. Russian.
5. Shilovskiy IP, Prozorova MS, Khaitov MR. Investigation of ergoferonto suppress activity of respiratory syncytial virus in vitro. Immunologiya. 2015;36(4):216-219. Russian.
6. Epstein OI. The phenomenon of release activity and the hypothesis of “spatial” homeostasis. Uspekhi Fiziol. Nauk. 2013;44(3):54-76. Russian.
7. Bailbé D, Philippe E, Gorbunov E, Tarasov S, Epstein O, Portha B. The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone. J. Diabetes Res. 2013;2013. ID 763125. doi: 10.1155/2013/763125.
8. Kim YH, Chang SH, Kwon JH, Rhee SS. HIV-1 Nef plays an essential role in two independent processes in CD4 downregulation: dissociation of the CD4-p56(lck) complex and targeting of CD4 to lysosomes. Virology. 1999;257(1):208-219.
9. Nakamura K, Yube K, Miyatake A, Cambier JC, Hirashima M. Involvement of CD4 D3-D4 membrane proximal extracellular domain for the inhibitory effect of oxidative stress on activation-induced CD4 down-regulation and its possible role for T cell activation. Mol. Immunol. 2003;39(15):909-921.
10. Nika K, Soldani C, Salek M, Paster W, Gray A, Etzensperger R, Fugger L, Polzella P, Cerundolo V, Dushek O, Höfer T, Viola A, Acuto O. Constitutively active Lck kinase in T cells drives antigen receptor signal transduction. Immunity. 2010;32(6):766-777.
11. Rao N, Miyake S, Reddi AL, Douillard P, Ghosh AK, Dodge IL, Zhou P, Fernandes ND, Band H. Negative regulation of Lck by Cbl ubiquitin ligase. Proc. Natl Acad. Sci. USA. 2002;99(6):3794-3799.
12. Saggioro D, Sorio C, Calderazzo F, Callegaro L, Panozzo M, Berton G, Chieco-Bianchi L. Mechanism of action of the monosialoganglioside GM1 as a modulator of CD4 expression. Evidence that GM1-CD4 interaction triggers dissociation of p56lck from CD4, and CD4 internalization and degradation. J. Biol. Chem. 1993;268(2):1368-1375.
13. Sizova LV. Treatment of early arthritis using arthrofoon (ultralow doses of antibodies to tumor necrosis factor-a). Indian J. Pharmacol. 2011;43(6):724-725.
14. Tarasov SA, Zarubaev VV, Gorbunov EA, Sergeeva SA, Epstein OI. Activity of ultra-low doses of antibodies to gammainterferon against lethal influenza A(H1N1)2009 virus infection in mice. Antiviral Res. 2012;93(2):219-224.
15. Uhlin M, Masucci MG, Levitsky V. Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes. Proc. Natl Acad. Sci. USA. 2005;102(26):9264-9269.